Triple-negative breast cancers share an aggressive biology, marked by increased
recurrence risk and poorer survival compared with hormone receptor—positive subtypes.
Few therapeutic trials have specifically focused on triple-negative breast cancer, and the
treatment of patients with early-stage triple-negative breast cancer has changed little in the
past decade. Over this time, however, attention has shifted to treatment approaches based
on molecular subtypes of breast cancer, and investigation into the mechanistic …